{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:04:24Z","timestamp":1792461864402,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 124678"],"award-info":[{"award-number":["R01 124678"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI109023"],"award-info":[{"award-number":["R01 AI109023"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R37 AI50234"],"award-info":[{"award-number":["R37 AI50234"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1201387"],"award-info":[{"award-number":["OPP1201387"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013134","name":"US Department of Defense Military Health System","doi-asserted-by":"publisher","award":["W81XWH-15-2-0033"],"award-info":[{"award-number":["W81XWH-15-2-0033"]}],"id":[{"id":"10.13039\/100013134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013134","name":"US Department of Defense Military Health System","doi-asserted-by":"publisher","award":["W81XWH-19-1-0086"],"award-info":[{"award-number":["W81XWH-19-1-0086"]}],"id":[{"id":"10.13039\/100013134","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.pt.2021.04.006","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T17:54:04Z","timestamp":1621014844000},"page":"709-721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4319-0647","authenticated-orcid":false,"given":"Ma\u00eblle","family":"Duffey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-6068","authenticated-orcid":false,"given":"Jeremy N.","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9796-847X","authenticated-orcid":false,"given":"Timothy N.C.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-8938","authenticated-orcid":false,"given":"David A.","family":"Fidock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-3204","authenticated-orcid":false,"given":"Didier","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2021.04.006_bb0005","series-title":"Global Technical Strategy for Malaria 2016\u20132030","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.pt.2021.04.006_bb0010","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/S2214-109X(17)30076-1","article-title":"Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and Plasmodium falciparum infection in Africa, 2003\u20132015: a modelling study using data from national surveys","volume":"5","author":"Bennett","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.pt.2021.04.006_bb0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1126\/science.aba0445","article-title":"Uncovering the ART of antimalarial resistance","volume":"367","author":"Marapana","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.04.006_bb0020","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"Uwimana","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2021.04.006_bb0025","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","article-title":"Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda","volume":"223","author":"Asua","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2021.04.006_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009133","article-title":"Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea","volume":"16","author":"Miotto","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2021.04.006_bb0035","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51015","article-title":"Local emergence in amazonia of Plasmodium falciparum K13 C580Y mutants associated with in vitro artemisinin resistance","volume":"9","author":"Mathieu","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.pt.2021.04.006_bb0040","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/AAC.50.5.1893-1895.2006","article-title":"Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic","volume":"50","author":"Dokomajilar","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0045","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.00875-06","article-title":"Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria","volume":"51","author":"Humphreys","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0050","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1128\/AAC.00968-08","article-title":"Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria","volume":"53","author":"Happi","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0055","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/infdis\/jiv551","article-title":"Artesunate\/amodiaquine versus artemether\/lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial","volume":"213","author":"Yeka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2021.04.006_bb0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12936-017-1712-4","article-title":"Efficacy of artemether\u2013lumefantrine, artesunate\u2013amodiaquine, and dihydroartemisinin\u2013piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015","volume":"16","author":"Plucinski","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2021.04.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00802-19","article-title":"Plasmodium falciparum kelch propeller polymorphisms in clinical isolates from Ghana from 2007 to 2016","volume":"63","author":"Matrevi","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0070","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/1475-2875-13-452","article-title":"Artemisinin resistance \u2013 modelling the potential human and economic costs","volume":"13","author":"Lubell","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2021.04.006_bb0075","first-page":"e338","article-title":"Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect","volume":"19","author":"Conrad","year":"2019","journal-title":"Dis."},{"key":"10.1016\/j.pt.2021.04.006_bb0080","series-title":"Antimicrobial Resistance Benchmark 2018","author":"Access to Medicine Foundation","year":"2018"},{"key":"10.1016\/j.pt.2021.04.006_bb0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2021.04.006_bb0090","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm.4381","article-title":"Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic","volume":"23","author":"Blasco","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2021.04.006_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003293","article-title":"Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families","volume":"9","author":"Bopp","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.pt.2021.04.006_bb0100","article-title":"Evidence of a mild mutator phenotype in Cambodian Plasmodium falciparum malaria parasites","volume":"11","author":"Lee","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2021.04.006_bb0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.15252\/emmm.201607295","article-title":"How to tackle antimalarial resistance?","volume":"9","author":"Leroy","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.pt.2021.04.006_bb0110","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1475-2875-11-292","article-title":"A framework for assessing the risk of resistance for anti-malarials in development","volume":"11","author":"Ding","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2021.04.006_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021914","article-title":"A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs","volume":"6","author":"McCarthy","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2021.04.006_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003203","article-title":"Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: a pilot and a randomised volunteer infection study in Australia","volume":"17","author":"Watts","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2021.04.006_bb0125","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial activity of single-dose DSM265, a novel Plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase","volume":"18","author":"Llanos-Cuentas","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2021.04.006_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa6645","article-title":"A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria","volume":"7","author":"Phillips","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.04.006_bb0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mib.2020.06.004","article-title":"The antimalarial resistome \u2013 finding new drug targets and their modes of action","volume":"57","author":"Carolino","year":"2020","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.pt.2021.04.006_bb0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/acsinfecdis.9b00371","article-title":"Setting our sights on infectious diseases","volume":"6","author":"De Rycker","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2021.04.006_bb0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1126\/science.aar4189","article-title":"Malaria parasite evolution in a test tube","volume":"359","author":"Carlton","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.04.006_bb0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1126\/science.aan4472","article-title":"Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics","volume":"359","author":"Cowell","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pt.2021.04.006_bb0155","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1128\/AAC.01224-16","article-title":"Metabolomic profiling of the Malaria Box reveals antimalarial target pathways","volume":"60","author":"Allman","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0160","doi-asserted-by":"crossref","first-page":"6650","DOI":"10.1128\/AAC.01226-16","article-title":"Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action","volume":"60","author":"Creek","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1568005043480989","article-title":"Proteomic approaches to studying drug targets and resistance in Plasmodium","volume":"4","author":"Cooper","year":"2004","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"10.1016\/j.pt.2021.04.006_bb0170","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41596-020-0310-z","article-title":"Cellular thermal shift assay for the identification of drug\u2013target interactions in the Plasmodium falciparum proteome","volume":"15","author":"Dziekan","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.pt.2021.04.006_bb0175","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.pt.2021.01.009","article-title":"MalDA, accelerating malaria drug discovery","volume":"37","author":"Yang","year":"2021","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2021.04.006_bb0180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-4939-9550-9_9","article-title":"Plasmodium falciparum in vitro drug resistance selections and gene editing","volume":"2013","author":"Ng","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.pt.2021.04.006_bb0185","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nbt.2925","article-title":"Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system","volume":"32","author":"Ghorbal","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.pt.2021.04.006_bb0190","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/mmi.13397","article-title":"CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs","volume":"101","author":"Ng","year":"2016","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pt.2021.04.006_bb0195","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-017-0007-4","article-title":"Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity","volume":"2","author":"Vanaerschot","year":"2017","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.pt.2021.04.006_bb0200","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00696-16","article-title":"Mutations in the Plasmodium falciparum cyclic amine resistance locus (PfCARL) confer multidrug resistance","volume":"7","author":"LaMonte","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.pt.2021.04.006_bb0205","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baraga\u00f1a","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.04.006_bb0210","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1128\/AAC.00519-09","article-title":"Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2R\u03b3null mice engrafted with human erythrocytes","volume":"53","author":"Jim\u00e9nez-D\u00edaz","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0215","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.pt.2014.07.004","article-title":"Defining the biology component of the drug discovery strategy for malaria eradication","volume":"30","author":"Leroy","year":"2014","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2021.04.006_bb0220","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm.3073","article-title":"Malaria biology and disease pathogenesis: insights for new treatments","volume":"19","author":"Miller","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2021.04.006_bb0225","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrmicro.2017.161","article-title":"Drug resistance in Plasmodium","volume":"16","author":"Haldar","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.pt.2021.04.006_bb0230","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1124\/pr.57.1.4","article-title":"Mechanisms of resistance of malaria parasites to antifolates","volume":"57","author":"Gregson","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pt.2021.04.006_bb0235","doi-asserted-by":"crossref","first-page":"9731","DOI":"10.1074\/jbc.M111.324319","article-title":"Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression","volume":"287","author":"Fisher","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2021.04.006_bb0240","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.tips.2006.09.005","article-title":"Transporters involved in resistance to antimalarial drugs","volume":"27","author":"Valderramos","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pt.2021.04.006_bb0245","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.04.006_bb0250","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","article-title":"Genetic markers associated with dihydroartemisinin\u2013piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype\u2013phenotype association study","volume":"17","author":"Amato","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2021.04.006_bb0255","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","article-title":"A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype\u2013genotype association study","volume":"17","author":"Witkowski","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2021.04.006_bb0260","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","article-title":"Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine","volume":"9","author":"Ross","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.04.006_bb0265","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-019-1795-x","article-title":"Structure and drug resistance of the Plasmodium falciparum transporter PfCRT","volume":"576","author":"Kim","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pt.2021.04.006_bb0270","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/AAC.03265-14","article-title":"Identification and deconvolution of cross-resistance signals from antimalarial compounds using multidrug-resistant Plasmodium falciparum strains","volume":"59","author":"Chugh","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0275","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1006\/expr.1995.1049","article-title":"Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro","volume":"80","author":"Canfield","year":"1995","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.pt.2021.04.006_bb0280","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1128\/AAC.02727-13","article-title":"KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission","volume":"58","author":"Kuhen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9735","article-title":"Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase","volume":"9","author":"Paquet","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.04.006_bb0290","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/AAC.04149-14","article-title":"Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum","volume":"59","author":"Stickles","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0295","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1021\/acsinfecdis.6b00025","article-title":"Plasmodium falciparum cyclic amine resistance locus (PfCARL), a resistance mechanism for two distinct compound classes","volume":"2","author":"Magistrado","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2021.04.006_bb0300","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","article-title":"Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies","volume":"13","author":"Witkowski","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2021.04.006_bb0305","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1093\/jac\/dkx279","article-title":"Comparison of the susceptibility of Plasmodium knowlesi and Plasmodium falciparum to antimalarial agents","volume":"72","author":"van Schalkwyk","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0310","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02519-17","article-title":"Enhanced ex vivo Plasmodium vivax intraerythrocytic enrichment and maturation for rapid and sensitive parasite growth assays","volume":"62","author":"Rangel","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2021.04.006_bb0315","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijpddr.2017.03.001","article-title":"Genetic diversity of next generation antimalarial targets: a baseline for drug resistance surveillance programmes","volume":"7","author":"Gomes","year":"2017","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2021.04.006_bb0320","doi-asserted-by":"crossref","first-page":"42","DOI":"10.12688\/wellcomeopenres.16168.1","article-title":"An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples","volume":"6","author":"Pearson","year":"2021","journal-title":"Wellcome Open Res."},{"key":"10.1016\/j.pt.2021.04.006_bb0325","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/mmi.13035","article-title":"Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter","volume":"97","author":"Petersen","year":"2015","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pt.2021.04.006_bb0330","first-page":"20153038","article-title":"Within-host competition and drug resistance in the human malaria parasite Plasmodium falciparum","volume":"283","author":"Bushman","year":"2016","journal-title":"Proc. Biol. Sci."},{"key":"10.1016\/j.pt.2021.04.006_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1636","article-title":"In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model","volume":"11","author":"Mandt","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.04.006_bb0350","doi-asserted-by":"crossref","first-page":"E5455","DOI":"10.1073\/pnas.1414221111","article-title":"(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium","volume":"111","author":"Jim\u00e9nez-D\u00edaz","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2021.04.006_bb0355","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1038\/ncomms6521","article-title":"Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum","volume":"5","author":"Vaidya","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2021.04.006_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aas9917","article-title":"Antimalarial pantothenamide metabolites target acetyl-coenzyme A biosynthesis in Plasmodium falciparum","volume":"11","author":"Schalkwijk","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2021.04.006_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001169","article-title":"The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites","volume":"9","author":"Delves","year":"2012","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2021.04.006_bb0340","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/nprot.2016.096","article-title":"Routine in vitro culture of P. falciparum gametocytes to evaluate novel transmission-blocking interventions","volume":"11","author":"Delves","year":"2016","journal-title":"Nat. Protoc."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492221000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492221000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:37:09Z","timestamp":1761464229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492221000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1471492221000866"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2021.04.006","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2021.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}